买手套送积分活动正在火热进行中,买一盒手套送50积分,积分可兑换iPhone6S plus
The RMP1-14 monoclonal antibody reacts with mouse PD-1 (programmed death-1) also known as CD279.
正品货源 质量保障
该货品暂时缺货,请在下面输入您的邮箱地址或手机号码,当我们有现货供应时,我们会发送邮件通知您!
产品描述: The RMP1-14 monoclonal antibody reacts with mouse PD-1 (programmed death-1) also known as CD279. PD-1 is a 50-55
kDa cell surface receptor encoded by the Pdcd1 gene that belongs to the CD28 family of the Ig superfamily. PD-1 is transiently
expressed on CD4 and CD8 thymocytes as well as activated T and B lymphocytes and myeloid cells. PD-1 expression declines
after successful elimination of antigen. Additionally, Pdcd1 mRNA is expressed in developing B lymphocytes during the pro-B-cell
stage. PD-1’s structure includes a ITIM (immunoreceptor tyrosine-based inhibitory motif) suggesting that PD-1 negatively regulates
TCR signals. PD-1 signals via binding its two ligands, PD-L1 and PD-L2 both members of the B7 family. Upon ligand binding, PD-1
signaling inhibits T-cell activation, leading to reduced proliferation, cytokine production, and T-cell death. Additionally, PD-1 is known
to play key roles in peripheral tolerance and prevention of autoimmune disease in mice as PD-1 knockout animals show dilated
cardiomyopathy, splenomegaly, and loss of peripheral tolerance. Induced PD-L1 expression is common in many tumors including
squamous cell carcinoma, colon adenocarcinoma, and breast adenocarcinoma. PD-L1 overexpression results in increased resistance
of tumor cells to CD8 T cell mediated lysis. In mouse models of melanoma, tumor growth can be transiently arrested via treatment
with antibodies which block the interaction between PD-L1 and its receptor PD-1. For these reasons anti-PD-1 mediated immunotherapies
are currently being explored as cancer treatments. Like the J43 antibody the RMP1-14 antibody has been shown to block the binding of
both mouse PD-L1-Ig and mouse PD-L2-Ig to PD-1.
客服热线:400-995-1995